Silence Therapeutics (SLN) Competitors

$6.54 +0.16 (+2.43%)

As of 03:13 PM Eastern

SLN vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CELUW

Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry.

Silence Therapeutics vs. Its Competitors

Silence Therapeutics (NASDAQ:SLN) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

: 98.7% of Silence Therapeutics shares are owned by institutional investors. 4.1% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
: 180 Life Sciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -294.20%. 180 Life Sciences' return on equity of 0.00% beat Silence Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Silence Therapeutics -294.20% -67.48% -40.47%
180 Life Sciences N/A N/A N/A
: 180 Life Sciences has lower revenue, but higher earnings than Silence Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Silence Therapeutics $43.26M N/A -$45.31M -$1.65 -3.96
180 Life Sciences N/A N/A N/A N/A N/A
: Silence Therapeutics presently has a consensus price target of $32.60, suggesting a potential upside of 398.85%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Silence Therapeutics is more favorable than 180 Life Sciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics
2 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.43
180 Life Sciences
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Silence Therapeutics had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 2 mentions for Silence Therapeutics and 0 mentions for 180 Life Sciences. Silence Therapeutics' average media sentiment score of 0.63 beat 180 Life Sciences' score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Silence Therapeutics Positive
180 Life Sciences Neutral

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-294.20%	-67.48%	-40.47%
180 Life Sciences	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$43.26M	N/A	-$45.31M	-$1.65	-3.96
180 Life Sciences	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
180 Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Silence Therapeutics	Positive
180 Life Sciences	Neutral

Summary

Silence Therapeutics beats 180 Life Sciences on 8 of the 11 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Subscribe Now

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLN vs. The Competition

Export to Excel

Metric	Silence Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$3.02B	$6.14B	$10.45B
Dividend Yield	N/A	57.77%	5.73%	4.78%
P/E Ratio	-3.96	22.95	85.06	27.10
Price / Sales	N/A	612.62	570.65	176.64
Price / Cash	N/A	172.63	37.39	61.86
Price / Book	1.46	5.40	12.40	6.66
Net Income	-$45.31M	$33.06M	$3.32B	$276.79M
7 Day Performance	26.89%	-1.86%	-0.23%	-1.40%
1 Month Performance	34.74%	12.03%	9.56%	5.64%
1 Year Performance	-64.71%	-2.98%	71.76%	37.04%

Silence Therapeutics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLN Silence Therapeutics	2.0721 of 5 stars	$6.54 +2.4%	$32.60 +398.9%	-65.1%	$0.00	$43.26M	-3.96	100	News Coverage
ATNFW 180 Life Sciences	N/A	$0.06 -7.7%	N/A	+585.9%	$0.00	N/A	0.00	7
LBPSW 4D pharma	N/A	N/A	N/A	N/A	$0.00	$522K	0.00	N/A
AIMDW Ainos	N/A	$0.23 +26.3%	N/A	N/A	$0.00	$110.87K	0.00	40	Gap Up
ALVOW Alvotech	N/A	$1.31 -11.8%	N/A	-49.5%	$0.00	$560.10M	0.00	4	Gap Up
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	$9.14M	0.00	20	High Trading Volume
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.03 +24.8%	N/A	-33.2%	$0.00	N/A	0.00	15	Gap Up
BFRIW Biofrontera	N/A	$0.10 +3.1%	N/A	+443.5%	$0.00	$39.19M	0.00	70	Gap Up
BTMDW biote	N/A	$0.01 +6.3%	N/A	N/A	$0.00	$199.07M	0.00	N/A
BCTXW BriaCell Therapeutics	N/A	$0.04 -12.4%	N/A	-83.8%	$0.00	N/A	0.00	8	Negative News Short Interest ↑
CELUW Celularity	N/A	$0.03 -24.6%	N/A	+112.8%	$0.00	$44.59M	0.00	220	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLN) was last updated on 10/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silence Therapeutics (SLN) Competitors

SLN vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CELUW

Silence Therapeutics vs. Its Competitors

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silence Therapeutics (SLN) Competitors

SLN vs. ATNFW, LBPSW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, BCTXW, and CELUW

Silence Therapeutics vs. Its Competitors

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools